Compass Therapeutics
phase combination safety data | Compass Therapeutics
Company
Deck Type
Sector
Industry
Deck date
May 2022
Slide
28 of 36
Similar slides by Compass Therapeutics
See diffirences between slides (animation)
Investor Presentation
May 2023
phase safety data | Compass Therapeutics
Investor Presentation
February 2023
phase safety data hei as observed in patient | Compass Therapeutics
Related slides by other companies
BioAtla
Investor Presentation
January 2024
phase cab treatment emergent adverse events non squamous | BioAtla
ATAI
Investor Presentation
October 2023
is well tolerated with a favorable safety profile demonstrated across clinical studies in patients dosed including up to the highest single dose of and daily dose of tid in two placebo controlled phase studies in over patients was dosed up to tid for six months rates of headache and gastrointestinal issues were comparable to placebo representing a differentiated profile from certain competitor programs in development for does not induce sedation which is distinct from agonists initial phase a study confirmed safety and tolerability profile in schizophrenia patients including on top of standard of care with no evidence of safety concerns on any of the safety measures labs physical exam vitals aes | ATAI
Immatics
Investor Presentation
November 2023
gen in cohort a most frequent adverse events | Immatics
Immatics
Investor Presentation
November 2023
gen in all melanoma patients at most frequent adverse events so | Immatics
Other recent decks by Compass Therapeutics
See all presentations (6 decks)
Investor Presentation
May 2023
Investor Presentation
February 2023
Investor Presentation
January 2023
Investor Presentation
May 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights